Nine years later, families of Lily Mine tragedy still seek justice
On the ninth anniversary of the Lily Mine tragedy, families of the victims expressed their frustrations over ongoing ...
Lily Mine tragedy: nine years later, families still seek justice
On the ninth anniversary of the Lily Mine tragedy, families of the victims express their frustrations over ongoing retrieval ...
MarketWatch18 天
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...
Investopedia18 天
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...
24/7 Wall St21 天
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 36.07% higher than today’s price of $756.99. Of the ...
Wall Street Journal22 天
Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...
BioSpace22 天
Lilly’s I&I Push Gains Momentum With Omvoh Expansion
Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according to analysts from BMO Capital Markets. The FDA on Wednesday signed off on ...
The Citizen22 天
IN PHOTOS: Curro Nelspruit’s Grade Ones take on their first day
The start of a new school year is always filled with joy and excitement, and this year is no exception for the Grade One learners at Curro Nelspruit.
Pharmaceutical Technology22 天
Lilly gains US FDA approval for Omvoh to treat Crohn’s disease
Visible healing of the intestinal lining was observed in 46% of subjects treated with the therapy. Credit: SewCreamStudio/Shutterstock. Eli Lilly has received ...
Managed Healthcare Executive22 天
FDA Approves Lilly’s Omvoh for Crohn's Disease, Second Indication
The FDA has approved Eli Lilly’s Omvoh (mirikizumab-mrkz) for the treatment of moderate to severe active Crohn's disease in adults according to a recent news release. This is its second indication. In ...
The Pharma Letter22 天
FDA approves Lilly's Omvoh for Crohn's disease
The US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz), from US pharma major Eli Lilly (NYSE: LLY), for the treatment of moderately to severely active Crohn's disease in ...
PMLiVE22 天
Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults
Eli Lilly’s Omvoh (mirikizumab-mrkz) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderately to severely active Crohn’s disease. Crohn’s disease is one of the ...